Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

被引：0
|
作者：
Alison R Meloni
Mary Beth DeYoung
Jenny Han
Jennie H Best
Michael Grimm
机构：
[1] Amylin Pharmaceuticals,
[2] LLC,undefined
来源：
Cardiovascular Diabetology | / 12卷
关键词：
Number needed to treat; Absolute benefit; Exenatide; Type 2 diabetes; Diabetes mellitus; ADA treatment guidelines; GLP-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
    Blonde, Lawrence
    Pencek, Richard
    MacConell, Leigh
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [42] Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system
    Li, Yang
    Han, Min-Min
    He, Qiong
    Liu, Zi-Ang
    Liang, Dong
    Hou, Jing-Tian
    Zhang, Yi
    Liu, Yun-Feng
    WORLD JOURNAL OF DIABETES, 2020, 11 (12) : 654 - 665
  • [43] A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
    Scott, D. A.
    Boye, K. S.
    Timlin, L.
    Clark, J. F.
    Best, J. H.
    DIABETES OBESITY & METABOLISM, 2013, 15 (03): : 213 - 223
  • [44] Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
    Abdi, Hengameh
    Azizi, Fereidoun
    Amouzegar, Atieh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 16 (02)
  • [45] Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine
    Secnik, K
    Hayes, C
    Matza, L
    Kim, S
    Oglesby, A
    Yurgin, N
    Brodows, R
    Malley, K
    VALUE IN HEALTH, 2005, 8 (06) : A155 - A156
  • [46] MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES
    Gaebler, J. A.
    Soto-Campos, G.
    Alperin, P. E.
    Hoogwerf, B. J.
    Wintle, M.
    Maggs, D.
    Han, J.
    Blickensderfer, A.
    Pencek, R.
    Bruhn, D.
    Peskin, B. R.
    VALUE IN HEALTH, 2011, 14 (03) : A91 - A91
  • [47] The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States
    Wood, Mollie E.
    Patorno, Elisabetta
    Huybrechts, Krista F.
    Bateman, Brian T.
    Gray, Kathryn J.
    Seely, Ellen W.
    Vine, Seanna
    Hernandez-Diaz, Sonia
    ENDOCRINOLOGY DIABETES & METABOLISM, 2022, 5 (02)
  • [48] Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
    Wysham, Carol H.
    Rosenstock, Julio
    Vetter, Marion L.
    Dong, Fang
    Ohman, Peter
    Iqbal, Nayyar
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 165 - 172
  • [49] COST-UTILITY OF EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [50] Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
    Braendle, M.
    Erny-Albrecht, K. M.
    Goodall, G.
    Spinas, G. A.
    Streit, P.
    Valentine, W. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (08) : 501 - 515
12345